Evidence map›Paper›PMID 30544220›Full record

ArticleCardiovascular research2019

Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression.

John Szendrey, Shawn M Lamothe, Stephanie Vanner, Jun Guo, Tonghua Yang, Wentao Li, Jordan Davis, Mala Joneja, Adrian Baranchuk, Shetuan Zhang

Open access · greenAbstract read
In one paragraph

Article in Cardiovascular research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John SzendreyDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Shawn M LamotheDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Stephanie VannerDivision of Rheumatology, Department of Medicine, Kingston General Hospital, Queen's University, Kingston, Canada.
Jun GuoDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Tonghua YangDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Wentao LiDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Jordan DavisDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Mala JonejaDivision of Rheumatology, Department of Medicine, Kingston General Hospital, Queen's University, Kingston, Canada.
Adrian BaranchukDivision of Cardiology, Department of Medicine, Kingston General Hospital, Queen's University, Kingston, Canada.
Shetuan ZhangDepartment of Biomedical and Molecular Sciences, Queen's University, 18 Stuart Street, Kingston, Canada.
Queen's University · CAKingston General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe human ether-a-go-go-related gene (hERG) encodes the rapidly activating delayed rectifier potassium channel (IKr). Malfunction of hERG/IKr is the primary cause of acquired long QT syndrome (LQTS), an electrical disorder of the heart that can cause arrhythmias and sudden death. Patients with autoimmune diseases display a high incidence of LQTS. While dysfunction of hERG channels induced by autoantibodies such as anti-Ro52 may play a role in this pathology, the underlying mechanisms are not well understood. Here, we investigated the acute and chronic effects of anti-Ro52 antibody on hERG channels stably expressed in human embryonic kidney (hERG-HEK) 293 cells as well as IKr in neonatal rat ventricular myocytes. METHODS AND

resultsUsing whole-cell patch clamp, western blot analyses, and immunocytochemistry, we found that a 12-h treatment of hERG-HEK cells with patients' sera containing anti-Ro52 autoantibody decreased the hERG current (IhERG) by 32% compared to cells treated with autoantibody-negative patients' sera. Commercial anti-Ro52 antibody at 100 µg/mL did not acutely block IhERG. Instead, a 12-h treatment with anti-Ro52 antibody at a concentration of 4 µg/mL significantly reduced mature hERG protein expression and IhERG. Specifically, anti-Ro52 antibody did not acutely block hERG current but chronically facilitated hERG endocytic degradation. The extracellular S5-pore linker of hERG, which forms the turret of the channel on the outside of the cell, is the target region for anti-Ro52-mediated hERG reduction since its replacement with the analogous region of EAG abolished the anti-Ro52 effect. In neonatal rat ventricular myocytes, 100 µg/mL anti-Ro52 antibody did not acutely block IKr, but a 12-h treatment of cells with 4 µg/mL anti-Ro52 antibody selectively reduced IKr and prolonged the action potential duration.

conclusionsOur results indicate that anti-Ro52 antibody acts on the hERG S5-pore linker to chronically decrease hERG expression and current. These findings provide novel insights into hERG regulation and anti-Ro52 antibody-associated LQTS.

Indexed as

AgedAnimalsAnimals, NewbornAntibodies, AntinuclearBinding Sites, AntibodyDown-RegulationERG1 Potassium ChannelFemaleHEK293 CellsHumansLong QT SyndromeMaleMembrane PotentialsMiddle AgedProtein BindingProtein Interaction Domains and MotifsAntibodies, AntinuclearERG1 Potassium ChannelKCNH2 protein, humanKcnh2 protein, ratSS-A antibodiesAnti-Ro52 antibodyCardiac electrophysiologyPotassium channels

Identifiers

PMID30544220
PMCPMC6648346
OpenAlexW2903685277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.